NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AUPH stock has increased by 2.8% and is now trading at $14.50.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.05. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%.
View Aurinia Pharmaceuticals' earnings history.

9 analysts have issued twelve-month target prices for Aurinia Pharmaceuticals' stock. Their forecasts range from $14.00 to $33.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $23.88 in the next twelve months. This suggests a possible upside of 64.7% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals.

News coverage about AUPH stock has been trending very positive on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totaling 4,580,000 shares, a decrease of 5.2% from the July 15th total of 4,830,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is currently 3.1 days. Approximately 5.2% of the company's stock are short sold.
View Aurinia Pharmaceuticals' Short Interest.

Some companies that are related to Aurinia Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Emergent Biosolutions (EBS), Bausch Health Companies (BHC), ACADIA Pharmaceuticals (ACAD), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), Schrodinger (SDGR), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Allakos (ALLK) and Evotec (EVTCY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Alibaba Group (BABA), Exelixis (EXEL), Novavax (NVAX) and Corbus Pharmaceuticals (CRBP).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.79%), Swiss National Bank (0.14%), Alps Advisors Inc. (0.12%), UBS Group AG (0.08%), CIBC Asset Management Inc (0.06%) and Quantitative Systematic Strategies LLC (0.02%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., UBS Group AG, and Patriot Financial Group Insurance Agency LLC.

AUPH stock was bought by a variety of institutional investors in the last quarter, including Alps Advisors Inc., CIBC Asset Management Inc, Swiss National Bank, Quantitative Systematic Strategies LLC, Exane Derivatives, ProShare Advisors LLC, and Zurcher Kantonalbank Zurich Cantonalbank .

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $14.50.

Aurinia Pharmaceuticals has a market capitalization of $1.83 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]